← Back to patent-cliff list
CAS 7677-24-9
Cyanotrimethylsilanetrimethylsilanecarbonitrile
Codes: (XI)101438-54-a, EFIN-012
Application context (from source-drug indications)
Breast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylateOnychomycosisEfinaconazolePancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxel
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Paclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
| Efinaconazole | Tier C — Watch / trade | - |
| Paclitaxel | Tier B — Position early | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
2-Methylpropionic acid ethyl ester→2-Propynyl bromide→Ethyl 2,2-dimethylpent-4-ynoate→2,2-Dimethylpent-4-ynoic acid→1-Chloro-3-methyl-2-butene→2,2-Dimethylpent-3-ynoic acid→N-Methoxy-N-methylamine hydrochloride→N-Methoxy-N,2,2-trimethylpent-3-ynamide→chloro(3-methylbut-2-en-1-yl)magnesium→2,6,6-Trimethylnon-2-en-7-yn-5-one→Cyanotrimethylsilane→5-Methyl-2-(2-methylpent-3-yn-2-yl)-2-[(trimethylsilyl)oxy]hex-4-enenitrile→5-Methyl-2-(2-methylpent-3-yn-2-yl)-2-[(trimethylsilyl)oxy]hex-4-enal→(2E)-1-[1,1,1,3,3,3-Hexamethyl-2-(trimethylsilyl)trisilan-2-yl]-2-[(2S)-2-methyl-2-[3-(trityloxy)propyl]cyclohexylidene]hydrazine→(3aS,7Z,9aS,13bS)-6,9a,14,14-Tetramethyl-9,9a,10,11,12,13b-hexahydro-4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxol-2-one→(1S,2S)-5-Methyl-2-(2-methylpent-3-yn-2-yl)-1-[(6S)-6-methyl-6-[3-(trityloxy)propyl]cyclohex-1-en-1-yl]hex-4-ene-1,2-diol→(4S,5S)-4-(3-Methylbut-2-en-1-yl)-4-(2-methylpent-3-yn-2-yl)-5-[(6S)-6-methyl-6-[3-(trityloxy)propyl]cyclohex-1-en-1-yl]-1,3-dioxolan-2-one→(4S,5S)-5-[(6S)-6-(3-Hydroxypropyl)-6-methylcyclohex-1-en-1-yl]-4-(3-methylbut-2-en-1-yl)-4-(2-methylpent-3-yn-2-yl)-1,3-dioxolan-2-one→(4S)-5-[(6S)-6-Allyl-6-methylcyclohex-1-en-1-yl]-4-(3-methylbut-2-en-1-yl)-4-(2-methylpent-3-yn-2-yl)-1,3-dioxolan-2-one
1H-1,2,4-triazole→1-(((2R,3S)-2-(2,4-difluorophenyl)-3-methyloxiran-2-yl)methyl)-1H-1,2,4-triazole→2-chloro-1-(2,4-difluorophenyl)ethan-1-one→trimethylsilanecarbonitrile→(((2S,3S,4R)-4-(4,5-difluoro-2-hydroxyphenoxy)-3-hydroxytetrahydro-2H-pyran-2-yl)methyl)diphenylphosphine oxide→(S)-3-chloro-2-(2,4-difluorophenyl)-2-((trimethylsilyl)oxy)propanenitrile→(S)-3-chloro-2-(2,4-difluorophenyl)-2-((trimethylsilyl)oxy)propanal→(2R,3R)-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butane-2,3-diol→4-methylenepiperidine
2-Methylpropionic acid ethyl ester→2-Propynyl bromide→Ethyl 2,2-dimethylpent-4-ynoate→2,2-Dimethylpent-4-ynoic acid→1-Chloro-3-methyl-2-butene→2,2-Dimethylpent-3-ynoic acid→N-Methoxy-N-methylamine hydrochloride→N-Methoxy-N,2,2-trimethylpent-3-ynamide→chloro(3-methylbut-2-en-1-yl)magnesium→2,6,6-Trimethylnon-2-en-7-yn-5-one→Cyanotrimethylsilane→5-Methyl-2-(2-methylpent-3-yn-2-yl)-2-[(trimethylsilyl)oxy]hex-4-enenitrile→5-Methyl-2-(2-methylpent-3-yn-2-yl)-2-[(trimethylsilyl)oxy]hex-4-enal→(2E)-1-[1,1,1,3,3,3-Hexamethyl-2-(trimethylsilyl)trisilan-2-yl]-2-[(2S)-2-methyl-2-[3-(trityloxy)propyl]cyclohexylidene]hydrazine→(3aS,7Z,9aS,13bS)-6,9a,14,14-Tetramethyl-9,9a,10,11,12,13b-hexahydro-4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxol-2-one→(1S,2S)-5-Methyl-2-(2-methylpent-3-yn-2-yl)-1-[(6S)-6-methyl-6-[3-(trityloxy)propyl]cyclohex-1-en-1-yl]hex-4-ene-1,2-diol→(4S,5S)-4-(3-Methylbut-2-en-1-yl)-4-(2-methylpent-3-yn-2-yl)-5-[(6S)-6-methyl-6-[3-(trityloxy)propyl]cyclohex-1-en-1-yl]-1,3-dioxolan-2-one→(4S,5S)-5-[(6S)-6-(3-Hydroxypropyl)-6-methylcyclohex-1-en-1-yl]-4-(3-methylbut-2-en-1-yl)-4-(2-methylpent-3-yn-2-yl)-1,3-dioxolan-2-one→(4S)-5-[(6S)-6-Allyl-6-methylcyclohex-1-en-1-yl]-4-(3-methylbut-2-en-1-yl)-4-(2-methylpent-3-yn-2-yl)-1,3-dioxolan-2-one
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.